TRex Bio (NASDAQ:TRXB) Major Shareholder Buys $2,499,994.00 in Stock

TRex Bio, Inc. (NASDAQ:TRXB) major shareholder Alexandria Venture Investments acquired 178,571 shares of the company’s stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $2,499,994.00. Following the completion of the purchase, the insider directly owned 1,346,501 shares in the company, valued at $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

TRex Bio Stock Up 4.9%

NASDAQ TRXB traded up $0.66 during trading hours on Thursday, hitting $14.16. 88,697 shares of the company’s stock were exchanged, compared to its average volume of 200,681. TRex Bio, Inc. has a 1-year low of $13.21 and a 1-year high of $15.50.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.